lilly novo nordisk - Search News

Order byBest matchMost fresh

Eli Lilly, Novo Nordisk and Weight loss

Novo Nordisk Stock Could Benefit From Eli Lilly’s Weight-Loss Price Hikes

The pricing of weight-loss and diabetes drugs like Lilly’s Zepbound and Mounjaro, and Novo’s Wegovy and Ozempic, is a pressure point for investors. Price erosion is a major worry amid increasing competition— including from knockoff versions of the drugs provided by telehealth pharmacies and coming patent expirations.

· 2d

Novo Nordisk's Lead Fades, Eli Lilly Holds Course For Outsized Gains, Says Analyst

· 2d

Weight-loss weariness and Trump threats wipe $250bn off Novo Nordisk and Eli Lilly

· 2d

Company hikes Mounjaro prices in the UK to make weight-loss drug cheaper in the US

Eli Lilly will significantly increase the price of its weight-loss drug Mounjaro in the United Kingdom in a bid to bring down prices in the United States after weeks of pressure from the Trump admini...

STAT · 2d

Pharmalittle: We’re reading about Lilly boosting prices in Europe, HHS reviving a vaccine task force, and more

Becker's Hospital Review · 2d

Eli Lilly pushes back on proposed tariffs

Eli Lilly Vs. Novo Nordisk: Correction Overly Done - GLP-1 Market Leadership/ Robust Pipelines Ahead

Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced return prospects. See more.

2don MSN

Novo Nordisk’s Wegovy Gets US Approval for Liver Disease

Novo Nordisk A/S’s blockbuster weight-loss drug Wegovy received Food and Drug Administration approval to treat a serious form of liver disease, beating rival Eli Lilly & Co. to the US market for the increasingly prevalent condition.

2don MSN

Why Novo Nordisk Flew Almost 3% Higher on Friday

It seems to be holding off on price adjustments demanded by President Trump.

3don MSN

Novo Nordisk debuts Wegovy in South Africa as weight-loss drugs race gathers pace

Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa and stepping up competition with Eli Lilly's Mounjaro which launched in the country eight months ago.

Eli Lilly Strikes $1.3 Billion Deal With Superluminal To Develop AI-Driven Obesity Drugs

Eli Lilly and Co (NYSE: LLY) has entered into a $1.3 billion deal with Superluminal Medicines to develop small-molecule drugs through artificial intelligence (AI) to treat obesity and other cardiometabolic diseases.